Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers

Jen Jung Pan, Nirav Thosani, Victor I. MacHicao, Michael B. Fallon

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

Livers from donors positive for antibody against anti-HBc can potentially transmit de novo hepatitis B (DNH) to their recipients. Despite a good outcome, prophylaxis is usually offered to such recipients. There is no consensus on the standard prophylactic regimen and hence prophylaxis varies among different transplant centres. Nonetheless, hepatitis B immune globulin (HBIG) is considered the mainstay of such prophylaxis, either alone or in combination with an oral antiviral treatment. We aim to provide a concise review of the current use of HBIG in prevention of DNH. We also address a few important questions regarding HBIG use.

Original languageEnglish (US)
Pages (from-to)635-643
Number of pages9
JournalHepatology International
Volume5
Issue number2
DOIs
StatePublished - Jun 2011

Keywords

  • De novo hepatitis B
  • Hepatitis B immune globulin
  • Liver transplant
  • Prophylaxis

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers'. Together they form a unique fingerprint.

Cite this